Idorsia Ltd Total Liabilities
Idorsia Ltd total liabilities. Based on the latest financial reports, Idorsia Ltd (IDIA) has total liabilities worth CHF1.66 Billion CHF (≈ $2.09 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Idorsia Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Idorsia Ltd (2016–2025)
Total liabilities of Idorsia Ltd from 2016 to 2025. This chart illustrates how Idorsia Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore IDIA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Idorsia Ltd Competitors by Total Liabilities
The table below lists competitors of Idorsia Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guanglian Aviation Industry Co Ltd
SHE:300900
|
China | CN¥3.01 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥823.87 Million |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
Mexico | MX$21.44 Billion |
|
Plejd AB (publ)
F:3CA
|
Germany | €346.32 Million |
|
Coretronic
TWO:5371
|
Taiwan | NT$27.69 Billion |
|
Baltic Classifieds Group PLC
LSE:BCG
|
UK | €95.38 Million |
|
Arcelik AS
IS:ARCLK
|
Turkey | TL513.70 Billion |
|
Focus Lightings Tech Co Ltd
SHE:300708
|
China | CN¥2.53 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Idorsia Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Idorsia Ltd total assets.
Liquidity & Leverage Metrics
Idorsia Ltd Total Liabilities Ratios Explained
Idorsia Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Idorsia Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Idorsia Ltd (2016–2025)
The table below shows the annual total liabilities of Idorsia Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF1.60 Billion ≈ $2.03 Billion |
-6.69% |
| 2024-12-31 | CHF1.72 Billion ≈ $2.17 Billion |
+16.98% |
| 2023-12-31 | CHF1.47 Billion ≈ $1.86 Billion |
-6.16% |
| 2022-12-31 | CHF1.57 Billion ≈ $1.98 Billion |
+13.52% |
| 2021-12-31 | CHF1.38 Billion ≈ $1.74 Billion |
+62.23% |
| 2020-12-31 | CHF849.88 Million ≈ $1.07 Billion |
+1.19% |
| 2019-12-31 | CHF839.85 Million ≈ $1.06 Billion |
+12.11% |
| 2018-12-31 | CHF749.14 Million ≈ $947.12 Million |
+35.62% |
| 2017-12-31 | CHF552.37 Million ≈ $698.34 Million |
+35.67% |
| 2016-12-31 | CHF407.15 Million ≈ $514.75 Million |
-- |
About Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the… Read more